Difference between revisions of "Neuroendocrine tumour of the pancreas"

Jump to navigation Jump to search
Line 88: Line 88:
==IHC==
==IHC==
*CK19 +ve -- should be done as a routine in pancreatic NETs; poor prognostic factor.<ref name=pmid19956064>{{Cite journal  | last1 = Jain | first1 = R. | last2 = Fischer | first2 = S. | last3 = Serra | first3 = S. | last4 = Chetty | first4 = R. | title = The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. | journal = Appl Immunohistochem Mol Morphol | volume = 18 | issue = 1 | pages = 9-15 | month = Jan | year = 2010 | doi = 10.1097/PAI.0b013e3181ad36ea | PMID = 19956064 }}</ref>
*CK19 +ve -- should be done as a routine in pancreatic NETs; poor prognostic factor.<ref name=pmid19956064>{{Cite journal  | last1 = Jain | first1 = R. | last2 = Fischer | first2 = S. | last3 = Serra | first3 = S. | last4 = Chetty | first4 = R. | title = The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. | journal = Appl Immunohistochem Mol Morphol | volume = 18 | issue = 1 | pages = 9-15 | month = Jan | year = 2010 | doi = 10.1097/PAI.0b013e3181ad36ea | PMID = 19956064 }}</ref>
*Chromogranin +ve.
*Synaptophysin +ve.
*CD56 +ve.
A panel:
*Chromogranin, synaptophysin, CD10, PR, beta-catenin, CK7, pankeratin, Ki-67, CK19.


Note:
Note:
*''CK19'' should '''not''' be confused with ''CA19-9''.
*''CK19'' should '''not''' be confused with ''CA19-9''.
A panel:
*Chromogranin, synaptophysin, CD10, PR, beta-catenin, CK7, pankeratin, Ki-67.


==Sign out==
==Sign out==
48,860

edits

Navigation menu